Dataset from A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients.

This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose
combination tablet administered once-a-day versus the individual tablets administered
twice-a-day within 3-drug combination regimens in ART (antiretroviral)-experienced HIV-1
infected patients.